Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury

JAMA

Volumn 310, Issue 23, 2013, Pages 2544-2553

  Gandhi, Sonja ^a   Fleet, Jamie L ^a   Bailey, David G ^b   McArthur, Eric ^a,c   Wald, Ron ^d   Rehman, Faisal ^a   Garg, Amit X ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FELODIPINE; NIFEDIPINE; VERAPAMIL;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; COHORT ANALYSIS; DRUG DOSE COMPARISON; DRUG POTENTIATION; FEMALE; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 84890333809     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282426     Document Type: Article

References (37)

1. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother. 2000;34(4):495-513.
2. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50(4):285-295.
3. Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869-876.
4. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther. 1997;61(4):410-415.
5. Glesby MJ, Aberg JA, Kendall MA, et al; Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium-channel blockers. Clin Pharmacol Ther. 2005;78(2):143-153.
6. Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD. Erythromycin- felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther. 1996;60(1):25-33.
7. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337(8736):268-269.
8. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol. 1996;51(2):189-193.
9. Liedholm H, Nordin G. Erythromycin-felodipine interaction. DICP. 1991;25(9):1007-1008.
10. Kaeser YA, Brunner F, Drewe J, Haefeli WE. Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health Syst Pharm. 1998;55(22):2417-2418.
11. Gerónimo-Pardo M, Cuartero-del-Pozo AB, Jiménez-Vizuete JM, Cortiñas-Sáez M, Peyró-García R. Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother. 2005;39(3):538-542.
12. Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005;39(2):357-360.
13. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following coprescription of macrolide antibiotics and calcium-channel blockers. CMAJ. 2011;183(3):303-307.
14. US Food and Drug Administration. BIAXIN Filmtab (clarithromycin tablets, USP) BIAXIN XL Filmtab (clarithromycin extended-release tablets) BIAXIN Granules (clarithromycin for oral suspension, USP). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/050662s048,050698s029,050775s018lbl.pdf. Accessed November 2, 2013.
15. Coca SG, Peixoto AJ, Garg AX, Krumholz HM, Parikh CR. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis. 2007;50(5):712-720.
16. Statistics Canada. Population by sex and age group, by province and territory. 2011. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/ demo31a-eng.htm. Accessed October 30, 2013.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349.
18. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67-71.
19. Zhao YY, Weir MA, Manno M, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med. 2012;156(8):560-569.
20. Shih AWY, Weir MA, Clemens KK, et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int. 2012;82(8):903-908.
21. Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol. 2011;22(5):939-946.
22. Siddiqui N, Coca SG, Devereaux PJ, et al. Secular trends in acute dialysis after major elective surgery - 1995 to 2009. CMAJ. 2012;184(11):1237- 1245.
23. Gandhi S, Shariff SZ, Beyea MM, et al. Identifying geographical regions serviced by hospitals to assess laboratory-based outcomes. BMJ Open. 2013;3(1).
24. Fleet JL, Shariff SZ, Bailey DG, et al. Comparing 2 types of macrolide antibiotics for the purpose of assessing population-based drug interactions. BMJ Open. 2013;3(7):1-8.
25. Food and Drug Administration. Drug development and drug interactions: table of substrates: inhibitors and inducers. 2011. http://www.fda.gov/drugs/ developmentapprovalprocess/developmentresources/druginteractionslabeling/ ucm093664.htm. Accessed October 30, 2013.
26. Hwang YJ, Shariff SZ, Gandhi S, et al. Validity of the International Classification of Diseases, 10th Revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission. BMJ Open. 2012;2(6):1-11.
27. Kidney Disease; Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. http://www.kdigo.org/clinical-practice-guidelines/pdf/KDIGO%20AKI%20Guideline. pdf. Accessed October 30, 2013.
28. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol. 1996;27(6):1335-1342.
29. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330(7497):960-962.
30. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between 2 groups in observational research. Comm Stat Simul Comput. 2009;38(6):1228-1234. doi:10.1080/03610910902859574.
31. Fleet JL, Dixon SN, Shariff SZ, et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol. 2013;14(1):81.
32. Compendium of Pharmaceuticals and Specialties. CPS 2012: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. 47th ed. Ottawa: Canadian Pharmaceutical Association; 2012.
33. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
34. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
35. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365-3370.
36. Sica DA. Calcium-channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich). 2005;7(4)(suppl 1):21-26.
37. Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med. 2004;140(9):714-720.